Recent advances in urinary bladder cancer detection

References

• Reynard J, Brewster S, Biers S. Oxford Handbook of Urology (2nd Edition). Oxford University Press, Oxford, UK (2009).
   Google Scholar
• Ries LA, Eisner MP, Kosary CL et al.SEER Cancer Statistics Review, 1975–2000. National Cancer Institute, MD, USA (2003).
   Google Scholar
• Ploeg M, Aben KKH, Kiemeny LA. The present and future burden of urinary bladder cancer in the world. World J. Urol.27(3), 289–293 (2009).
   PubMed Web of Science ®Google Scholar
• Ferlay J, Randi G, Bosetti C et al. Declining mortality from bladder cancer in Europe. BJU Int.101(1), 11–19 (2008).
   PubMed Web of Science ®Google Scholar
• El-Bokainy MN, Mokhtar NM, Ghoneim MA, Hussein MH. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer48, 2643–2648 (1981).
   Google Scholar
• Mostafa MH, Sheweita SA, O’Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin. Microbiol.1, 97–111 (1999).
   Google Scholar
• Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol.18, 581–592 (2007).
   PubMed Web of Science ®Google Scholar
• Vrtiska TJ, Hartman RP, Kofler JM et al. Spatial resolution and radiation dose of a 64-MDCT scanner compared with published CT urography protocols. AJR Am. J. Roentgenol.192, 941–948 (2009).
   Google Scholar
• Sanchez-Ortiz RF, Huang WC, Mick R et al. An interval of longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J. Urol.169, 110–115 (2003).
   PubMed Web of Science ®Google Scholar
• Varkarakis MJ, Gaeta J, Moore RH et al. Superficial bladder tumor: aspects of clinical progression. Urology4, 414–420 (1974).
   PubMedGoogle Scholar
• Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int.97, 301–305 (2006).
   PubMed Web of Science ®Google Scholar
• Sutton JM. Evaluation of haematuria in adults. JAMA263, 2475–2480 (1990).
   PubMed Web of Science ®Google Scholar
• Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1939 patients with hematuria to evaluate current diagnostic practice. J. Urol.163, 524–527 (1999).
   Google Scholar
• Golin Al, Howard RS. Asymptomatic microscopic hematuria. J. Urol.124, 389–391 (1980).
   PubMed Web of Science ®Google Scholar
• Mohr DN, Offord KP, Owen RA, Melton LJ 3rd. Asymptomatic microhematuria and urologic disease. A population based study. JAMA256, 224–229 (1986).
   PubMedGoogle Scholar
• Messing EM, Vaillancourt A. Hematuria screening for bladder cancer. J. Occup. Med.32, 838–845 (1990).
   PubMedGoogle Scholar
• Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis). J. Urol.162, 1697–1701 (1999).
   PubMed Web of Science ®Google Scholar
• Palou J, Rodriguez-Rubio F, Huguet J et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumours. J. Urol.174(3), 859–861 (2005).
   Google Scholar
• Cowan NC, Turney BW, Taylor NJ et al. Multidetector computed tomography urography (MDCTU) for diagnosing upper urinary tract tumour. BJU Int.99, 1363–1370 (2007).
   PubMed Web of Science ®Google Scholar
• Albani JN, Ciaschini MW, Streem SB et al. The role of computerized tomographic urography in the initial evaluatin of haematuria. J. Urol.177, 644–648 (2007).
   PubMedGoogle Scholar
• Fritz GA, Schoellnast H, Deutschmann HA et al. Multiphasic multidetector-row CT (MDCT) in detection and staging of transitional cell carcinomas of the upper urinary tract. Eur. Radiol.16, 1244–1252 (2006).
   Google Scholar
• Gray Sears C, Ward JF, Sears ST et al. Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhaematuria. J. Urol.168, 2457–2460 (2003).
   Google Scholar
• Liu W, Mortele KJ, Silverman SG. Incidental extraurinary findings at MDCT urography in patients with hematuria: prevalence and impact on imaging costs. AJR Am. J. Roentgenol.185, 1051–1056 (2005).
   Google Scholar
• Bhatt JR, Ali I, Fung THM et al. CT urogram for haematuria – unearthing other diagnoses: a study of 801 patients. Eur. Urol.10(Suppl. 2), 72 (2011).
   Google Scholar
• Cohan RH, Caoili EM, Cowan NC, Weizer AZ, Ellis JH. MDCT Urography: exploring a new paradigm for imaging of bladder cancer. AJR Am. J. Roentgenol.192, 1501–1508 (2009).
   PubMedGoogle Scholar
• Sadow CA, Silverman SG, O’Leary MP, Signorovitch JE. Bladder cancer detection with CT urography in an academic medical center. Radiology249, 195–202 (2008).
   PubMed Web of Science ®Google Scholar
• Turney BW, Willatt JMC, Nixon D, Crew JP, Cowan NC. Computed tomography for diagnosing bladder cancer. BJU Int.98, 345–348 (2006).
   PubMed Web of Science ®Google Scholar
• Blick CGT, Nazir SA, Mallett S et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int.110(1), 84–94 (2011).
   Google Scholar
• Knox MK, Cowan NC, Rivers-Bowerman MD, Turney BW. Evaluation of multidetector computed tomography urography and ultrasonography for diagnosing bladder cancer. Clin. Radiol.63, 1317–1325 (2008).
   PubMedGoogle Scholar
• Goessi C, Knispel HH, Millar K et al. Is routine excretory urography necessary at first diagnosis of bladder cancer? J. Urol.157(2), 480–481 (1997).
   Google Scholar
• Merkle EM, Fleiter T, Wunderlich A, Rilinger N, Gorich J, Sokiranski R. [Virtual cystoscopy based on spiral CT data]. Rofo165(6), 582–585 (1996).
   Google Scholar
• Vining DJ, Zagoria RJ, Liu K et al. CT cystoscopy: an innovation in bladder imaging. AJR Am. J. Roentgenol.166, 409–410 (1996).
   PubMed Web of Science ®Google Scholar
• Zlotta A. What is the future of virtual cystoscopy in urology? Can. Urol. Assoc. J.5(1), 38–39 (2011).
   Google Scholar
• Qu X, Huang X, Wu L, Huang G, Ping X, Yan W. Comparison of virtual cystoscopy and ultrasonography for bladder cancer detection: a meta-analysis. Eur. J. Radiol.80(2), 188–197 (2011).
   Google Scholar
• Karabacak OR, Cakmakci E, Ozturk U et al. Virtual cystoscopy: the evaluation of bladder lesions with computed tomographic virtual cystoscopy. Can. Urol. Assoc. J.5(1), 34–37 (2011).
   Web of Science ®Google Scholar
• Lokeshwar VB, Habuchi T, Grossman HB et al. Bladder tumour markers beyond cytology: international consensus panel on bladder tumour markers. Urology66(6 Suppl. 1), 35–63 (2005).
   PubMed Web of Science ®Google Scholar
• Glas AS, Roos D, Deutekom M et al. Tumour markers in the diagnosis of primary bladder cancer. A systematic review. J. Urol.169(6), 1975–1982 (2003).
   PubMed Web of Science ®Google Scholar
• Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumour markers versus cytology: results of a comprehensive literature review and meta-analysis. Urology61(1), 109–118 (2003).
   PubMed Web of Science ®Google Scholar
• Van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur. Urol.47(6), 736–748 (2005).
   PubMed Web of Science ®Google Scholar
• Van Rhijn BWG, van der Poel HG, van der Kwast TH. Cytology and urinary markers for the diagnosis of bladder cancer. Eur. Urol. Suppl.8, 536–541 (2009).
   Google Scholar
• Vrooman OPJ, Witjes JA. Urinary markers in bladder cancer. Eur. Urol.53(5), 909–916 (2008).
   PubMed Web of Science ®Google Scholar
• Lotan Y, Shariat SF, Schmitz-Drager BJ et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol. Oncol.28(4), 441–448 (2010).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA293(7), 810–816 (2005).
   PubMed Web of Science ®Google Scholar
• Lotan Y, Svatek RS, Malats N. Screening for bladder cancer: a perspective. World J. Urol.26(1), 13–18 (2008).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Soloway M, Messing E et al. Surveillance for recurrent bladder cancer using a point-of-care proreomic assay. JAMA295(3), 299–305 (2006).
   PubMed Web of Science ®Google Scholar
• Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol. Oncol.26(6), 645–651 (2008).
   Google Scholar
• Mowatt G, Zhu S, Kilonzo M et al. Systematic review of the clinical effectiveness and costeffectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol. Assess.14(4), 1–331 (2010).
   Web of Science ®Google Scholar
• Schmitz-Drager BJ, Beiche B, Tirsar LA et al. Immunocytology in the assessment of patients with asymptomatic microhaematuria. Eur. Urol.51(6), 1582–1588 (2007).
   PubMed Web of Science ®Google Scholar
• Schlomer BJ, Ho R, Sagalowsky A et al. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J. Urol.183(1), 62–67 (2010).
   PubMed Web of Science ®Google Scholar
• Lotan Y, Shariat SF, Grp NS. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int.101(11), 1362–1367 (2008).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Marberger MJ, Lotan Y et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J. Urol.176(6), 919–926 (2006).
   PubMed Web of Science ®Google Scholar
• Nguyen CT, Jones JS. Defining the role of NMP22 in bladder cancer surveillance. World J. Urol.26(1), 51–58 (2008).
   PubMed Web of Science ®Google Scholar
• Babjuk M, Soukup V, Pesl M et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology71(4), 718–722 (2008).
   PubMed Web of Science ®Google Scholar
• Raitanen MP. The role of BTA stat test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J. Urol.26(1), 45–50 (2008).
   PubMed Web of Science ®Google Scholar
• Yutkin V, Nisman B, Pode D. Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance? Expert Rev. Anticancer Ther.10(6), 787–790 (2010).
   PubMed Web of Science ®Google Scholar
• Hong YM, Loughlin KR. Economic impact of tumor markers in bladder cancer surveillance. Urology71(1), 131–135 (2008).
   PubMed Web of Science ®Google Scholar
• Rodgers M, Nixon J, Hempel S et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol. Assess.10(18), iii–ix, xi–259 (2006).
   Web of Science ®Google Scholar
• Clayman RV, Reddy P, Lange PH. Flexible fiberoptic and rigid-rod lens endoscopy of the lower urinary tract: a prospective controlled comparison. J. Urol.131, 715–716 (1984).
   Google Scholar
• Pavone-Macaluso M, Lamartina M, Pavone C, Vella M. The flexible cystoscope. Int. Urol. Nephrol.24, 239–242 (1992).
   Google Scholar
• Burke DM, Shackley DC, O’Reilly PH. The community-based morbidity of flexible cystoscopy. BJU Int.89, 347–349 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson MI, Merrilees D, Robson WA et al. Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. BJU Int.100, 826–829 (2007).
   PubMed Web of Science ®Google Scholar
• Taghizadeh AK, El Madani A, Gard PR, Li CY, Thomas PJ, Denyer SP. When does it hurt? Pain during flexible cystoscopy in men. Urol. Int.76, 301–303 (2006).
   Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol.49(3), 466–465 (2006).
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K et al. EORTC Genito–Urinary Tract Cancer Collaborative Group. Variability in the recurrence Rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol.41(5), 523–531 (2002).
   PubMed Web of Science ®Google Scholar
• Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur. Urol.57(5), 843–849 (2010).
   PubMed Web of Science ®Google Scholar
• Lamm DL. Carcinoma in situ. Urol. Clin. North Am.19(3), 499–508 (1992).
   PubMed Web of Science ®Google Scholar
• Takenaka A, Yamada Y, Miyake H et al. Clinical outcomes of bacillus Calmette–Guérin instillation therapy for carcinoma in situ of urinary bladder. Int. J. Urol.15(4), 309–313 (2008).
   PubMed Web of Science ®Google Scholar
• Cauberg EC, de Bruin DM, Faber DJ, van Leeuwen TG, de la Rosette JJ, de Reijke TM. A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. Eur. Urol.56(2), 287–296 (2009).
   PubMed Web of Science ®Google Scholar
• Schmidbauer J, Witjes F, Schmeller N et al. Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J. Urol.171(1), 135–138 (2004).
   PubMed Web of Science ®Google Scholar
• Jichlinski P, Guillou L, Karlsen SJ et al. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for photodiagnosis of superficial bladder cancer – a multicenter study. J. Urol.170(1), 226–229 (2003).
   PubMed Web of Science ®Google Scholar
• Hungerhuber E, Stepp H, Kriegmair M et al. Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology69(2), 260–264 (2007).
   PubMed Web of Science ®Google Scholar
• Zaak D, Karl A, Knuchel R et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int.96, 217–222 (2005).
   PubMed Web of Science ®Google Scholar
• Jocham D, Witjes F, Wagner S et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, Phase III multicenter study. J. Urol.174, 862–866 (2005).
   PubMed Web of Science ®Google Scholar
• Kausch I, Sommerauer M, Montorsi F et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur. Urol.57(4), 595–606 (2010).
   PubMed Web of Science ®Google Scholar
• Draga RO, Grimbergen MC, Kok ET et al. Photodynamic diagnosis (5 aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette–Guérin immunotherapy and mitomycin C intravesical therapy. Eur. Urol.57(4), 655–660 (2010).
   PubMed Web of Science ®Google Scholar
• Burger M, Stief CG, Zaak D et al. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumours. Urology74(6), 1282–1286 (2009).
   Google Scholar
• Mowatt G, N’Dow J, Vale L et al. Photodynamic diagnosis of bladder cancer compared to white light cystoscopy: systematic review and meta-analysis. Int. J. Technol. Assess. Health Care27(1), 3–10 (2011).
   Web of Science ®Google Scholar
• Witjes JA, Redorta JP, Jacqmin D et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur. Urol.57(4), 607–614 (2010).
   PubMed Web of Science ®Google Scholar
• Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int.108(7), 1119–1123 (2011).
   PubMed Web of Science ®Google Scholar
• Natalin RA, Landman J. Where next for the endoscope? J. Nat. Rev. Urol.6, 622–628 (2009).
   Google Scholar
• Patel P, Bryan RT, Wallace DMA. Emerging endoscopic and photodynamic techniques for bladder cancer detection and surveillance. ScientificWorldJournal11, 2550–2558 (2011).
   Google Scholar
• Bryan RT, Billingham LJ, Wallace DMA. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int.101(6), 702–705 (2008).
   PubMed Web of Science ®Google Scholar
• ASGE Technology Committee et al. Narrow band imaging and multiband imaging. Gastrointest. Endosc.67, 581–589 (2008).
   PubMed Web of Science ®Google Scholar
• Bryan RT, Shah ZH, Collins SI, Wallace DMA. Narrow-band imaging flexible cystoscopy: a new user’s experience. J. Endourol.24(8), 1339–1343 (2010).
   PubMed Web of Science ®Google Scholar
• Herr H, Donat M, Dalbagni G, Taylor J. Narrow-band imaging cystoscopy to evaluate bladder tumours – individual surgeon variability. BJU Int.106(1), 53–55 (2010).
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Hayashino Y, Jackson JL, Takagaki S, Hinotsu S, Kawakami K. Diagnostic performance of chromoendoscopy and narrow band imaging for colonic neoplasms: a meta-analysis. Colorectal Dis.14(1), 18–28 (2012).
   PubMed Web of Science ®Google Scholar
• Mannath J, Subramaniam V, Hawkey CJ, Ragunath K. Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barretts esophagus: a meta-analysis. Endoscopy42(5), 351–359 (2010).
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int.102(9), 1111–1114 (2008).
   PubMed Web of Science ®Google Scholar
• Raitanen M-P, Aine R, Rintala E et al. FinnBladder Group. Differences between local and review urinary cytology and diagnosis of bladder cancer. An interobserver multicenter analysis. Eur. Urol.41(3), 284–289 (2002).
   PubMed Web of Science ®Google Scholar
• Koshikawa T, Leyh H, Schenck U. Difficulties in evaluating urinary specimens after local mitomycin therapy of bladder cancer. Diagn. Cytopathol.5, 117–121 (1989).
   PubMed Web of Science ®Google Scholar
• Badalament RA, Hermensen DK, Kimmel M et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology and voided cytology in the detection of bladder carcinoma. Cancer60, 1423–1427 (1987).
   PubMed Web of Science ®Google Scholar
• Viswanath S, Zelhof B, Ho E, Sethia K, Mills R. Is routine urine cytology useful in the haematuria clinic? Ann. R. Coll. Surg. Engl.90, 153–155 (2008).
   PubMed Web of Science ®Google Scholar
• Hofland CA, Mariani AJ. Is cytology required for a hematuria evaluation? J. Urol.171, 324–326 (2004).
   Google Scholar
• Nam RK, Redelmeier DA, Speiss PE, Sampson HA, Fradet Y, Jewett MA. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. J. Urol.163(3), 752–757 (2000).
   Google Scholar
• Lotan Y, Roehrborn CG. Cost effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J. Urol.167(1), 75–79 (2002).
   PubMed Web of Science ®Google Scholar
• Miladi M, Peyromaure M, Zerbib M et al. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur. Urol.43(3), 241–245 (2003).
   PubMed Web of Science ®Google Scholar
• Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J. Urol.165(3), 808–810 (2001).
   PubMed Web of Science ®Google Scholar
• Schips L, Augustin H, Zigeuner RE et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology59(2), 220–223 (2002).
   PubMed Web of Science ®Google Scholar
• Grimm MO, Steinhoff CH, Simon X et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J. Urol.170(2 Pt 1), 433–437 (2003).
   PubMed Web of Science ®Google Scholar
• Divrik RT, Yildirim Ü, Zorlu F et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumours of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol.175(5), 1641–1644 (2006).
   PubMed Web of Science ®Google Scholar
• Jahnson S, Wiklund F, Duchek M et al. Results of second-look resection after primary resection of T1 tumour of the urinary bladder. Scand. J. Urol. Nephrol.39(3), 206–210 (2005).
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Bassi P, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur. Urol.45(3), 257–266 (2004).
   PubMedGoogle Scholar
• Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? Cancer107(5), 982–990 (2006).
   PubMed Web of Science ®Google Scholar
• Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J. Urol.148, 788–789 (1992).
   PubMed Web of Science ®Google Scholar
• Naoe M, Ogawa Y, Morita J et al. Detection of circulating urothelial cancer cells in the blood using the CellSearch system. Cancer109(7), 1439–1445 (2007).
   PubMed Web of Science ®Google Scholar
• Guzzo TJ, McNeil BK, Bivalacqua TJ, Elliott DJ, Sokoll LJ, Schoenberg MP. The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urol. Oncol.30(1), 44–48 (2012).
   PubMedGoogle Scholar
• Shapiro A, Gofrit ON, Pizov G, Cohen JK, Maier J. Raman molecular imaging: a novel spectroscopic technique for diagnosis of bladder cancer in urine specimens. Eur. Urol.59(1), 106–112 (2011).
   PubMed Web of Science ®Google Scholar
• Lerner SP. Innovations in endoscopic imaging for bladder cancer. Eur. Urol.56(6), 920–922 (2009).
   Google Scholar
• Karl A, Stepp H, Willmann E et al. Optical coherence tomography for bladder cancer – ready as a surrogate for optical biopsy? Results of a prospective mono-centre study. Eur. J. Med. Res.15(3), 131–134 (2010).
   PubMed Web of Science ®Google Scholar
• Muldoon TJ, Anandasabapathy S, Maru D, Richards-Kortum R. High-resolution imaging in Barrett’s esophagus: a novel, low-cost endoscopic microscope. Gastrointest. Endosc.68(4), 737–744 (2008).
   PubMed Web of Science ®Google Scholar
• Roelants M, Huygems A, Crnolatac I et al. Evans blue as a selective dye marker for white-light diagnosis of non-muscle-invasive bladder cancer: an in vitro study. BJU Int.109, 300–305 (2011).
   Google Scholar
• Lu YY, Chen JH, Liang JA et al. Clinical value of FDG PET/CT in urinary bladder cancer: a systematic review and meta-analysis. Eur. J. Radiol. doi:10.1016/j.ejrad.07.018 (2011) (Epub ahead of print).
   Google Scholar
• Kompier LC, Lurkin I, van der Aa MN et al.FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE5(11), e13821 (2010).
   PubMed Web of Science ®Google Scholar